Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model

Journal of Genetics and Genomics

Volumn 36, Issue 6, 2009, Pages 355-361

  Mi, Ruifang ^a   Ma, Jianhui ^a   Zhang, Dechang ^a   Li, Limin ^a   Zhang, Hongbing ^a  

^a Postdoctoral Research Station Institute of Basic Medicine Sciences CAMS and PUMC   (China)

Author keywords

ERK MAPK; mTOR; PD98059; rapamycin; TSC

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; RAPAMYCIN; TUBERIN;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; DOSE RESPONSE; DRUG MECHANISM; ENZYME INHIBITION; FIBROBLAST CULTURE; GENE MUTATION; KNOCKOUT GENE; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; TUBEROUS SCLEROSIS COMPLEX 2 GENE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HUMANS; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA;

EID: 67149131861     PISSN: 16738527     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1673-8527(08)60124-1     Document Type: Article

References (31)

1. Bissler J.J., McCormack F.X., Young L.R., Elwing J.M., Chuck G., Leonard J.M., Schmithorst V.J., Laor T., Brody A.S., Bean J., Salisbury S., and Franz D.N. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358 (2008) 140-151
2. Brachmann S., Fritsch C., Maira S.M., and Garcia-Echeverria C. PI3K and mTOR inhibitors-a new generation of targeted anticancer agents. Curr. Opin. Cell Biol. 21 (2009) 1-5
3. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., Papa A., Nardella C., Cantley L.C., Baselga J., and Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118 (2008) 3065-3074
4. Castro A.F., Rebhun J.F., Clark G.J., and Quilliam L.A. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 278 (2003) 32493-32496
5. Chan J.A., Zhang H., Roberts P.S., Jozwiak S., Wieslawa G., Lewin-Kowalik J., Kotulska K., and Kwiatkowski D.J. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: Biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J. Neuropathol. Exp. Neurol. 63 (2004) 1236-1242
6. Cloughesy T.F., Yoshimoto K., Nghiemphu P., Brown K., Dang J., Zhu S., Hsueh T., Chen Y., Wang W., Youngkin D., Liau L., Martin N., Becker D., Bergsneider M., Lai A., Green R., Oglesby T., Koleto M., Trent J., Horvath S., Mischel P.S., Mellinghoff I.K., and Sawyers C.L. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5 (2008) e8
7. Crino P.B. Do we have a cure for tuberous sclerosis complex?. Epilepsy Curr. 8 (2008) 159-162
8. Crino P.B., Nathanson K.L., and Henske E.P. The tuberous sclerosis complex. N. Engl. J. Med. 355 (2006) 1345-1356
9. Curatolo P., Bombardieri R., and Jozwiak S. Tuberous sclerosis. Lancet 372 (2008) 657-668
10. Dabora S.L., Jozwiak S., Franz D.N., Roberts P.S., Nieto A., Chung J., Choy Y.S., Reeve M.P., Thiele E., Egelhoff J.C., Kasprzyk-Obara J., Domanska-Pakiela D., and Kwiatkowski D.J. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 68 (2001) 64-80
11. Davies D.M., Johnson S.R., Tattersfield A.E., Kingswood J.C., Cox J.A., McCartney D.L., Doyle T., Elmslie F., Saggar A., de Vries P.J., and Sampson J.R. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N. Engl. J. Med. 358 (2008) 200-203
12. +/- mouse model of tuberous sclerosis. Nat. Med. 14 (2008) 843-848
13. El-Hashemite N., Zhang H., Henske E.P., and Kwiatkowski D.J. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 361 (2003) 1348-1349
14. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., Chirieac L.R., Kaur R., Lightbown A., Simendinger J., Li T., Padera R.F., Garcia-Echeverria C., Weissleder R., Mahmood U., Cantley L.C., and Wong K.K. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14 (2008) 1351-1356
15. Garami A., Zwartkruis F.J., Nobukuni T., Joaquin M., Roccio M., Stocker H., Kozma S.C., Hafen E., Bos J.L., and Thoma G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11 (2003) 1457-1466
16. Grant S. Cotargeting survival signaling pathways in cancer. J. Clin. Invest. 118 (2008) 3003-3006
17. Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N.R., Cheng S., Shepherd P.R., Gout I., Downe C.P., and Lam R.F. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell. Biol. 166 (2004) 213-223
18. Inoki K., Li Y., Xu T., and Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17 (2003) 1829-1834
19. Kinkade C.W., Castillo-Martin M., Puzio-Kuter A., Yan J., Foster T.H., Gao H., Sun Y., Ouyang X., Gerald W.L., Cordon-Cardo C., and Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 118 (2008) 3051-3064
20. Kuang Y.H., Chen X., Su J., Wu L.S., Liao L.Q., Li D., Chen Z.S., and Kanekura T. RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. Cancer Lett. 276 (2009) 189-195
21. Kwiatkowski D.J., Zhang H., Bandura J.L., Heiberger K.M., Glogauer M., el-Hashemite N., and Onda H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11 (2002) 525-534
22. Lee L., Sudentas P., Donohue B., Asrican K., Worku A., Walker V., Sun Y., Schmidt K., Albert M.S., El-Hashemite N., Lader A.S., Onda H., Zhang H., Kwiatkowski D.J., and Dabora S.L. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42 (2005) 213-227
23. Manning B.D., and Cantley L.C. AKT/PKB signaling: Navigating downstream. Cell 129 (2007) 1261-1274
24. Paul E., and Thiele E. Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis. N. Engl. J. Med. 358 (2008) 190-192
25. Potter C.J., Pedraza L.G., and Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell. Biol. 4 (2002) 658-665
26. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., Botero M.L., Llonch E., Atzori F., Di Cosimo S., Maira M., Garcia-Echeverria C., Parra J.L., Arribas J., and Baselga J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68 (2008) 8022-8030
27. Shah O.J., Wang Z., and Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14 (2004) 1650-1656
28. Stommel J.M., Kimmelman A.C., Ying H., Nabioullin R., Ponugoti A.H., Wiedemeyer R., Stegh A.H., Bradner J.E., Ligon K.L., Brennan C., Chin L., and DePinho R.A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318 (2007) 287-290
29. Tee A.R., Manning B.D., Roux P.P., Cantley L.C., and Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13 (2003) 1259-1268
30. Zhang H., Bajraszewski N., Wu E., Wang H., Moseman A.P., Dabora S.L., Griffin J.D., and Kwiatkowski D.J. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest. 117 (2007) 730-738
31. Zhang H., Cicchetti G., Onda H., Koon H.B., Asrican K., Bajraszewski N., Vazquez F., Carpenter C.L., and Kwiatkowsk D.J. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 112 (2003) 1223-1233